Santhera Pharmaceuticals Holding AG

Santhera reported first-half 2026 revenue of CHF 48.3 million, up by over 100% year over year, driven by strong AGAMREE sales and recognition of income from the Nxera license deal. Product sales increased 48% year over year; royalties and milestones were CHF 29.1 million; revenue from supply of products and services was CHF 2.1 million; operating expenses declined 8.4% to CHF 25 million; operating loss narrowed to CHF 6.6 million from CHF 35.4 million a year earlier; and cash was CHF 41.8 million at June 30, 2026. Full-year 2026 guidance was unchanged: revenue of CHF 80 million to CHF 90 million, product sales growth of more than 50%, royalties expected to increase year over year, operating expenses of CHF 50 million to CHF 55 million, and cash broadly stable through year-end. Management said cash would decline in the first half of 2027 because of a mandatory German price reduction effective January 1, 2027 and inventory timing, but return to cash generation in the second half of 2027, without needing additional funding.

Orlando Oliveira struck an upbeat tone, saying 2026 had been a strong year so far and highlighting execution across market access, partnerships, and long-term data. He emphasized that the strategy remains centered on expanding AGAMREE directly in Europe, securing reimbursement in France and other midsized markets, and adding partner-led growth in APAC and Latin America. He also said the company will keep pursuing additional late-stage rare disease assets and possible indication expansions through partners to broaden the business beyond a single product.

Catherine Isted focused on the financial outperformance and the company’s guidance discipline. She cited CHF 48.3 million of first-half revenue, CHF 29.1 million of royalties and milestones, CHF 25 million of operating expenses, and CHF 41.8 million of cash, while reiterating full-year revenue guidance of CHF 80 million to CHF 90 million and OpEx of CHF 50 million to CHF 55 million. She also explained that the cash outlook is affected by an unexpected German pricing discount of about 8.5% starting in Q1 2027 and by inventory purchases moving into Q1 2027, but said the company would remain operationally cash positive and would not need extra funding.

Analysts focused on how to sustain growth and cash generation, especially after management had previously guided to cash flow breakeven in Q3 2026. Management said the business is operationally cash positive excluding milestones and financing costs, but cash timing will fluctuate because of milestone receipts and payments; they also said the revised guidance does not assume any additional sales milestones in H2. Questions also centered on Germany’s unexpected pricing discount, with management clarifying it is an 8.5% additional discount on top of list-price mechanics and should not create knock-on pricing pressure in other markets. Additional Q&A covered launch acceleration, market share by country, LatAm partnering timing, in-licensing strategy, and whether MFN pricing is still slowing U.S. partnering interest; management said MFN remains a concern for some U.S. biotechs, but pediatric rare diseases are less exposed.